An IL-8 inhibitor for use in the prevention and/or treatment of chemotherapy-induced neuropathy, wherein said IL-8 inhibitor is: a compound of formula (I) wherein - R1 is hydrogen or CH 3 ; - R2 is hydrogen or linear C 1 -C 4 alkyl, preferably it is hydrogen; - Y is a heteroatom selected from S, O and N; preferably it is S; - Z is selected from halogen, linear or branched C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 alkoxy, hydroxyl, carboxyl, C 1 -C 4 acyloxy, phenoxy, cyano, nitro, amino, C 1 -C 4 acylamino, halo C 1 -C 3 alkyl, halo C 1 -C 3 alkoxy, benzoyl, linear or branched C 1 -C 8 alkanesulfonate, linear or branched C 1 -C 8 alkanesulfonamide, linear or branched C 1 -C 8 alkylsulfonylmethyl; preferably it is trifluoromethyl; - X is OH or a residue of formula NHR 3 ; wherein R 3 is selected from: - hydrogen, hydroxyl, linear or branched C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 2 -C 6 alkenyl, C 1 -C 5 alkoxy, or - C 1 -C 6 phenylalkyl, wherein alkyl, cycloalkyl or alkenyl group can be substituted by a COOH residue, or - a residue of formula SO 2 R4 wherein R4 is C 1 -C 2 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 3 haloalkyl; or a compound of formula (II) or a pharmaceutically acceptable salt thereof, wherein: - R 4 is linear or branched C 1 -C 6 alkyl, benzoyl, phenoxy, trifluoromethanesulfonyloxy; preferably it is selected from benzoyl, isobutyl and trifluoromethanesulfonyloxy. - R 5 is H or linear or branched C 1 -C 3 alkyl, preferably it is H; - R 6 is linear or branched C 1 -C 6 alkyl or trifluoromethyl; preferably, it is a linear or branched C 1 -C 6 alkyl, more preferably it is CH 3 . - R1 is hydrogen or CH 3 ; - R2 is hydrogen or linear C 1 -C 4 alkyl, preferably it is hydrogen; - Y is a heteroatom selected from S, O and N; preferably it is S; - Z is selected from halogen, linear or branched C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 alkoxy, hydroxyl, carboxyl, C 1 -C 4 acyloxy, phenoxy, cyano, nitro, amino, C 1 -C 4 acylamino, halo C 1 -C 3 alkyl, halo C 1 -C 3 alkoxy, benzoyl, linear or branched C 1 -C 8 alkanesulfonate, linear or branched C 1 -C 8 alkanesulfonamide, linear or branched C 1 -C 8 alkylsulfonylmethyl; preferably it is trifluoromethyl; - X is OH or a residue of formula NHR 3 ; wherein R 3 is selected from: - hydrogen, hydroxyl, linear or branched C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 2 -C 6 alkenyl, C 1 -C 5 alkoxy, or - C 1 -C 6 phenylalkyl, wherein alkyl, cycloalkyl or alkenyl group can be substituted by a COOH residue, or - a residue of formula SO 2 R4 wherein R4 is C 1 -C 2 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 3 haloalkyl; - hydrogen, hydroxyl, linear or branched C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 2 -C 6 alkenyl, C 1 -C 5 alkoxy, or - C 1 -C 6 phenylalkyl, wherein alkyl, cycloalkyl or alkenyl group can be substituted by a COOH residue, or - a residue of formula SO 2 R4 wherein R4 is C 1 -C 2 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 3 haloalkyl; - R 4 is linear or branched C 1 -C 6 alkyl, benzoyl, phenoxy, trifluoromethanesulfonyloxy; preferably it is selected from benzoyl, isobutyl and trifluoromethanesulfonyloxy. - R 5 is H or linear or branched C 1 -C 3 alkyl, preferably it is H; - R 6 is linear or branched C 1 -C 6 alkyl or trifluoromethyl; preferably, it is a linear or branched C 1 -C 6 alkyl, more preferably it is CH 3 . <EOS>